Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17758714 | 0.88 | BACE1 (1.00) | BACE1BACE2 | |
| SCHEMBL13469334 | 0.85 | BACE1 (0.84) | BACE1BACE2 | |
| SCHEMBL20628771 | 0.85 | BACE1 (0.76) | BACE1BACE2 | |
| SCHEMBL17780183 | 0.84 | BACE1 (1.00) | BACE1BACE2 | |
| SCHEMBL17006953 | 0.84 | BACE1 (1.00) | BACE1BACE2 | |
| SCHEMBL16461320 | 0.82 | BACE1 (0.78) | BACE1BACE2 | |
| SCHEMBL16461321 | 0.82 | BACE1 (0.71) | BACE1BACE2 | |
| SCHEMBL20623292 | 0.81 | BACE1 (1.00) | BACE1BACE2 | |
| SCHEMBL20623405 | 0.81 | BACE1 (1.00) | BACE1BACE2 | |
| SCHEMBL20623291 | 0.81 | BACE1 (1.00) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218362-B1 | 2-AMINO-3,5-DIFLUORO-3,6-DIMETHYL-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS FOR TREATING ALZHEIMER'S DISEASE | H LUNDBECK AS (DK) | 2019-01-09 | — | — | EP | claimed |
| US-10059669-B2 | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treating alzheimer's disease | H. LUNDBECK A/S (DK) | 2018-08-28 | — | — | US | claimed |
| US-20170313658-A1 | 2-Amino-3,5-Difluoro-3,6-Dimethyl-6-Phenyl-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors for Treating Alzheimer's Disease | H. LUNDBECK A/S (DK) | 2017-11-02 | — | — | US | claimed |
| US-20250257124-A1 | ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF | H. LUNDBECK A/S (DK) | 2025-08-14 | — | — | US | disclosed |
| US-12129289-B2 | Antibodies specific for hyperphosphorylated tau and methods of use thereof | H. LUNDBECK A/S (DK) | 2024-10-29 | — | — | US | disclosed |
| US-20220177557-A1 | ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF | H. LUNDBECK A/S (DK) | 2022-06-09 | — | — | US | disclosed |
| EP-3878864-A1 | ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF | H. Lundbeck A/S (DK) | 2021-09-15 | — | — | EP | disclosed |
| US-11111290-B2 | Antibodies specific for hyperphosphorylated tau and methods of use thereof | H. LUNDBECK A/S (DK) | 2021-09-07 | — | — | US | disclosed |
| EP-3484916-B1 | ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF | H LUNDBECK AS (DK) | 2021-03-03 | — | — | EP | disclosed |
| US-10647762-B2 | Antibodies specific for hyperphosphorylated tau and methods of use thereof | H. LUNDBECK A/S (DK) | 2020-05-12 | — | — | US | disclosed |
| US-20200109192-A1 | ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF | H. LUNDBECK A/S (DK) | 2020-04-09 | — | — | US | disclosed |
| US-10472415-B2 | Antibodies specific for hyperphosphorylated tau and methods of use | H. LUNDBECK A/S (DK) | 2019-11-12 | — | — | US | disclosed |
| US-20190284266-A1 | ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF | H. LUNDBECK A/S (DK) | 2019-09-19 | — | — | US | disclosed |
| US-20190284265-A1 | ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF | H. LUNDBECK A/S (DK) | 2019-09-19 | — | — | US | disclosed |
| EP-3218362-B1 | 2-AMINO-3,5-DIFLUORO-3,6-DIMETHYL-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS FOR TREATING ALZHEIMER'S DISEASE | H LUNDBECK AS (DK) | 2019-01-09 | — | — | EP | disclosed |
| US-10059669-B2 | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treating alzheimer's disease | H. LUNDBECK A/S (DK) | 2018-08-28 | — | — | US | disclosed |
| US-20180016330-A1 | Antibodies Specific for Hyperphosphorylated Tau and Methods of Use Thereof | H. LUNDBECK A/S (DK) | 2018-01-18 | — | — | US | disclosed |
| US-20170313658-A1 | 2-Amino-3,5-Difluoro-3,6-Dimethyl-6-Phenyl-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors for Treating Alzheimer's Disease | H. LUNDBECK A/S (DK) | 2017-11-02 | — | — | US | disclosed |
| US-20170313658-A1 | 2-Amino-3,5-Difluoro-3,6-Dimethyl-6-Phenyl-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors for Treating Alzheimer's Disease | H. LUNDBECK A/S (DK) | 2017-11-02 | — | — | US | disclosed |
| WO-2016075062-A1 | 2-AMINO-3,5-DIFLUORO-3,6-DIMETHYL-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS FOR TREATING ALZHEIMER'S DISEASE | H. LUNDBECK A/S (DK) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284265-A1 | ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF | MAPT, PSEN2, PSEN1 | BACE1 86/4885BACE2 196/4885 |
| US-20190284266-A1 | ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF | MAPT, PSEN2, PSEN1 | BACE1 86/4885BACE2 196/4885 |
| US-20180016330-A1 | Antibodies Specific for Hyperphosphorylated Tau and Methods of Use Thereof | MAPT, PSEN2, PSEN1 | BACE1 86/4885BACE2 196/4885 |
| US-10059669-B2 | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treating alzheimer's disease | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885 |
| US-20220177557-A1 | ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF | MAPT, PSEN2, PSEN1 | BACE1 66/4885BACE2 154/4885 |
| US-11111290-B2 | Antibodies specific for hyperphosphorylated tau and methods of use thereof | MAPT, PSEN2, PSEN1 | BACE1 86/4885BACE2 196/4885 |
| US-20170313658-A1 | 2-Amino-3,5-Difluoro-3,6-Dimethyl-6-Phenyl-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors for Treating Alzheimer's Disease | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885 |
| US-20250257124-A1 | ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF | MAPT, PSEN2, PSEN1 | BACE1 86/4885BACE2 196/4885 |
| US-10472415-B2 | Antibodies specific for hyperphosphorylated tau and methods of use | MAPT, PSEN2, PSEN1 | BACE1 111/4885BACE2 210/4885 |
| US-10647762-B2 | Antibodies specific for hyperphosphorylated tau and methods of use thereof | MAPT, PSEN2, PSEN1 | BACE1 86/4885BACE2 196/4885 |
| US-20200109192-A1 | ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF | MAPT, PSEN2, PSEN1 | BACE1 66/4885BACE2 154/4885 |
| US-12129289-B2 | Antibodies specific for hyperphosphorylated tau and methods of use thereof | MAPT, PSEN2, PSEN1 | BACE1 86/4885BACE2 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.